Plasma (Octaplas) - Octapharma

Drug Profile

Plasma (Octaplas) - Octapharma

Alternative Names: Octaplas

Latest Information Update: 29 Feb 2012

Price : $50

At a glance

  • Originator Octapharma
  • Class Blood products and substitutes
  • Mechanism of Action Blood coagulation factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Blood coagulation disorders; Haemorrhage; Thrombotic thrombocytopenic purpura

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 29 Feb 2004 Launched for Coagulation disorders in Finland (IV)
  • 29 Feb 2004 Launched for Haemorrhage in Finland (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top